Table 1.

Main characteristics of patients admitted in the two time periods of the SARS-CoV-2 infection.

	Period 1 (March 1 to April 13) N=416	Period 2 (April 14 to May 12) N=106	p value
Age (years)	67.5±15	73.1±16.7	0.001
Male gender	255 (61.3)	51 (48.5)	0.015
Obesity*	87 (31.4)	16 (20.3)	0.07
Arterial hypertension	241 (57.9%)	56 (52.8)	0.38
Diabetes mellitus	125 (30)	16 (15)	0.002
Cardiomyopathy	107 (25.7)	23 (21.7)	0.45
Chronic obstructive pulmonary disease	70 (16.8)	14 (13.2)	0.38
Chronic renal failure	66 (15.9)	24 (22.6)	0.10
History of cancer	110 (26.4)	27 (25.4)	0.90
Chronic liver disease	12 (2.9)	6 (5.7)	0.23
Autoimmune diseases	33 (7.9)	6 (5.7)	0.54
Symptoms upon presentation
Cough or dyspnea	232 (55.8)	43 (40.6)	0.006
Sputum production	49 (11.8)	2 (1.9)	0.002
Chest pain	53 (12.7)	5 (4.7)	0.023
Syncope	21 (5.1)	4 (3.7)	0.63
Clinical signs upon presentation
Systolic blood pressure (mmHg)	127±21	130±24	0.20
Body temperature (°C)	37.5±1.0	37.1±1.1	0.001
Heart rate (bpm)	86±17	87±22	0.68
C-reactive protein (mg/dL)	8.6±7.5	7.3±6.1	0.12
In-hospital therapy
Hydroxychloroquine*	325 (89.0)	73 (80.2)	0.034
Lopinavir/ritonavir	70 (16.8)	5 (4.7)	0.002
Remdesivir	8 (1.9)	0	0.22
Tocilizumab	45 (10.8)	1 (0.9)	0.002
Low molecular weight heparin*	286 (78.4)	84 (85.7)	0.12

Data are expressed as n (%) or mean±standard deviation. * Data were missing for obesity in 166 patients (139 in period 1 and 27 in period 2), for hydroxychloroquine in 66 patients (51 in period 1 and 15 in period 2) and for low molecular weight heparin in 59 patients (51 in period 1 and 8 in period 2).